ADMA Q1 2022 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$29M+81.3% YoY

Gross Profit

$4M12.6% margin

Operating Income

-$15M-50.9% margin

Net Income

-$25M-85.9% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

+10.3%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$29M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$308M

Total Liabilities

$181M

Stockholders' Equity

$127M

Cash & Equivalents

$70M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$29M	$16M	+81.3%
Gross Profit	$4M	-$2M	+312.7%
Operating Income	-$15M	-$15M	+2.3%
Net Income	-$25M	-$18M	-36.1%

Revenue Segments

Product Revenue

$29M100%

License Revenue

$35,7080%

Geographic Segments

United States

$27M100%